Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
about
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practiceDelay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer."Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit.The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of CholangiocarcinomaPrognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
P2860
Q28084982-11FE1C1B-523D-4CF7-8D85-903D84B36D71Q35915735-ABB12A09-784D-49FD-A092-D3EF66E4DC7EQ36343040-345D3DD8-07D6-4FCF-833D-94CFB5ED33E6Q36473001-9120944B-F6CA-4612-8A04-91BDD77EE0C4Q36754437-5BAF5DD9-6074-43A7-B5F5-EBF660EA89CBQ36908374-5F81732A-86C7-4467-AC2B-2EBF59C46596Q37109643-ED8D793A-54F9-4C72-B59A-AA9011D39EC9Q38693444-E0DF2F69-D70E-4C36-9B84-B8841C4E3E6AQ39226891-9A0A753F-0486-42E9-ADB0-19884DB5C842Q39330528-9196D68A-DD51-4E21-9640-540901E180DFQ42700840-1276034C-E737-460F-B240-B573B8E5C106Q51673307-E40A7D5D-A337-4707-BC81-47DD6A5C73A6
P2860
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@ast
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@en
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@nl
type
label
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@ast
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@en
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@nl
prefLabel
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@ast
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@en
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@nl
P2093
P2860
P50
P1476
Outcomes of HER2-positive earl ...... analysis. The RETROHER study.
@en
P2093
Andrea Michelotti
Angela Vaccaro
Francesco Giotta
Ilaria Bertolini
Laura Pizzuti
Lucia Mentuccia
Luigi Di Lauro
Marcella Mottolese
Marcello Maugeri-Saccà
Patrizia Seminara
P2860
P2888
P304
P356
10.1007/S10549-014-3133-1
P407
P50
P577
2014-09-19T00:00:00Z
P5875
P6179
1035836586